Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus

ورودی‌های بالینی بیمار

حداقل ۷۰ — حداکثر ۱۰۰۰ • واحد: mg/dL

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
irae grade
—grade
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • —1–1
  • —2–2
  • —3–3
  • —4–4
Direct Clinical Answer

The Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include fasting glucose mg dl. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. Routine clinical application promotes standardized evidence-based patient management.

Clinical Guidelines & Evidence

Grades severity of hyperglycemia secondary to immune checkpoint inhibitor therapy and provides management recommendations

Clinical Indication

The Immune-Related Adverse Events for Endocrine Toxicities - Diabetes Mellitus is indicated for bedside clinical practice to support Grades severity of hyperglycemia secondary to immune checkpoint inhibitor therapy and provides management recommendations. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Multidisciplinary team approach recommended (oncology, endocrinology, pharmacy).

Formula & Variables:

Grading based on fasting glucose levels (mg/dL), presence of ketosis/T1DM evidence, and symptom severity: Grade 1 (>160 mg/dL, no ketosis, mild symptoms), Grade 2 (160-250 mg/dL OR ketosis at any level, moderate symptoms), Grade 3 (250-500 mg/dL, severe symptoms), Grade 4 (>500 mg/dL, life-threatening symptoms)

Input Parameters

NameTypeRequiredDescription
fasting_glucose_mg_dlfloatYesFasting glucose level in mg/dL(mg/dL)
ketosis_or_t1dm_evidencestringYesEvidence of ketosis or Type 1 Diabetes Mellitus at any glucose level
symptom_severitystringYesPatient symptom severity and functional status

Score Interpretation & Guidance

RangeStageDescription
1–1—Mild - Asymptomatic or mild symptoms
2–2—Moderate - Moderate symptoms, able to perform ADLs
3–3—Severe - Severe symptoms, unable to perform ADLs
4–4—Life-threatening - Severe symptoms, life-threatening consequences

Evidence-Based References (EBM)

  • Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385.DOI: 10.1200/JCO.2017.77.6385
  • Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar 1;18(3):230-241. doi: 10.6004/jnccn.2020.0012.DOI: 10.6004/jnccn.2020.0012
  • Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, et al. Collateral Damage: Insulin-Dependent Diabetes Induced by Immune Checkpoint Inhibitors. Diabetes. 2018 Aug;67(8):1471-1480. doi: 10.2337/dbi18-0002.DOI: 10.2337/dbi18-0002
  • Akturk HK, Alkanani A, Karanchi H, Nair V, Michels AW, Ostrom QT, et al. Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis. Diabet Med. 2019 Sep;36(9):1075-1081. doi: 10.1111/dme.14050.DOI: 10.1111/dme.14050

Related calculators